The IPO Buzz
IPO Calendar
Last Week's IPO Traffic
Pricings
2015 Pricings
Last 100 IPOs
Last 12 Months
IPOs by Managers
By Industry
Secondary Offerings
IPO Pipeline
SCOOP Ratings
IPOs Recently Filed
IPOs by Managers
By Industry
Secondary Offerings
Archives
SCOOP Track Record From 2000 to Present
IPO Traffic by Week
IPO Index
Biocept 
General Information
Business: We are a cancer diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, tests utilizing a standard blood sample. These tests (including our OncoCEE-BRTM breast cancer CTC test, which is already on the market) are designed to provide information to oncologists to enable them to select appropriate treatment for their patients due to better, timelier and more-detailed data on the characteristics of tumors. Our marketed test and our tests in development for the detection and analysis of CTCs utilize our Cell Enrichment and Extraction, or CEE®, technology, and our tests in development for the detection and analysis of ctDNA utilize our CEE-Selector™ technology, each performed on a standard blood sample.
Industry: MEDICAL LABORATORIES
Employees: 27 Founded: 1997
Contact Information
Address: 5810 Nancy Ridge Drive, San Diego, CA 92121, US
Phone: 858-320-8200
Web Address: www.biocept.com
View Prospectus: Biocept
Financial Information
Market Cap: $ 47.3 mil
Revenues: $ 0.1 mil (last 12 months)
Net Income: $ -9.7 mil (last 12 months)
IPO Profile
Symbol: BIOC
Shares (millions): 1.9
Price Range: $10.00 - $10.00
Est.$ Volume $ 19.0 mil
Manager / Joint Managers Aegis Capital
Co Managers Feltl and Company/ MLV & Co.
Expected to Trade 2/5/2014
Status Priced
SCOOP RATING Available only to Subscribers
RATING CHANGE Available only to Subscribers


 
© 2024 IPOSCOOP.com All rights reserved.